Stanley Crooke - ISIS Pharmaceuticals Chairman of the Board and Presidentident, CEO

Chairman

Dr. Stanley T. Crooke M.D. Ph.D. is Chairman of the Board President Chief Executive Officer of Ionis Pharmaceuticals Inc Dr. Crooke is a founder of Ionis and was Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis from 1980 until January 1989 Dr. Crooke worked for SmithKline Beckman Corporation a pharmaceutical company where his titles included President of Research and Development of SmithKline and French Laboratories. The Board believes Dr. Crooke is uniquely suited to serve on the Board primarily because as the Chief Executive Officer and founder of Ionis he has dedicated over 26 years to discovering and developing antisense our technology platform. He is the named inventor on some of the key patents in the field of RNAtargeted therapeutics and has over 30 years of drug discovery and development experience. since 1991.
Age 69
Tenure 33 years
Professional MarksPh.D
Phone760-931-9200
Webhttp://www.isispharm.com
Crooke is a founder of Isis and was Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Isis, from 1980 until January 1989, Dr. Crooke was employed by SmithKline Beckman Corporationrationrationration, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories.

ISIS Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1) % which means that it has lost $0.1 on every $100 spent on assets. This is way below average. ISIS Pharmaceuticals' management efficiency ratios could be used to measure how well ISIS Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 472.07 M in liabilities with Debt to Equity (D/E) ratio of 1.92, which is about average as compared to similar companies. ISIS Pharmaceuticals has a current ratio of 6.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ISIS Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, ISIS Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ISIS Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ISIS to invest in growth at high rates of return. When we think about ISIS Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

CHAIRMAN Age

Roderick WendtJeld Wen Holding
66
Donald WashkewiczParker Hannifin
64
Steven ReidEldorado Gold Corp
64
Kirk HachigianJeld Wen Holding
58
Robert GilmoreEldorado Gold Corp
64
Dale CormanWestern Copper And
N/A
Paul BarberServiceNow
53
Matthew RossJeld Wen Holding
43
Gary MichelJeld Wen Holding
58
Thomas WilliamsParker Hannifin
65
MA BAIoneer Ltd American
66
Luvleen SidhuBm Technologies
37
George AlbinoEldorado Gold Corp
61
Steve ReidEldorado Gold Corp
63
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. ISIS Pharmaceuticals (ISIS) is traded on NASDAQ Exchange in USA and employs 390 people.

Management Performance

ISIS Pharmaceuticals Leadership Team

Elected by the shareholders, the ISIS Pharmaceuticals' board of directors comprises two types of representatives: ISIS Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ISIS. The board's role is to monitor ISIS Pharmaceuticals' management team and ensure that shareholders' interests are well served. ISIS Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ISIS Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Joseph Loscalzo, Director
Joseph Klein, Independent Director
Joseph Wender, Independent Director
Wade Walke, Executive Director - Corporate Communications
Sarah Boyce, Chief Business Officer
Brett Monia, Sr. VP of Drug Discovery and Corporate Devel.
Frank Bennett, Senior Vice President - Antisense Research
Stanley Crooke, Chairman of the Board and Presidentident, CEO
Elizabeth Hougen, CFO and Sr. VP of Fin.
Richard Geary, Sr. VP of Devel.
Spencer Berthelsen, Independent Director
Frederick Muto, Independent Director
Breaux Castleman, Independent Director
Patrick ONeil, Senior Vice President - Legal, General Counsel
Lynne Parshall, COO, Corporate Secretary, Director

ISIS Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ISIS Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ISIS Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ISIS Pharmaceuticals' short interest history, or implied volatility extrapolated from ISIS Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Other Consideration for investing in ISIS Stock

If you are still planning to invest in ISIS Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ISIS Pharmaceuticals' history and understand the potential risks before investing.
Commodity Directory
Find actively traded commodities issued by global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA